Skip to main content

Table 1 Studies comparing amiodarone and beta blockers

From: Treatment strategies for new onset atrial fibrillation in patients treated on an intensive care unit: a systematic scoping review

Authors Sample size and setting Primary diagnosis Study design and risk of bias Intervention Rate control outcome Rhythm control outcome Mortality outcome
Walkey et al. (2016) n = 3174a (NOAF patients)
Setting: USA
Sepsis Retrospective comparative
Risk of bias: Serious
Beta blockers (metoprolol, esmolol, atenolol, labetalol, propranolol) versus amiodarone Not assessed Not assessed Hospital: RRb 0.67 (95% CI 0.59–0.77)
Matsumoto et al. (2015) (conference abstract) n = 276
n = 116 (amiodarone)
n = 160 (landiolol)
Setting: Japan ICU
Not reported Retrospective comparative
Risk of bias: Critical
Amiodarone versus landiolol Not assessed NSc
Amiodarone: 50%
Landiolol: 67%
Not assessed
Balik et al. (2017) n = 234d
n = 177 (amiodarone)
n = 15 (metoprolol)
Setting: Czech Republic
general ICU
Septic shock Retrospective comparative
Risk of bias: Critical
Amiodarone versus metoprolol Not assessed Amiodarone: 74%
Metoprolol: 92%
ICU: NS
Hospital: NS
Mieure et al. (2011) (conference abstract) n = 126e
n = 61 (amiodarone)
n = 24 (metoprolol)
Setting: USA ICU
Not reported Retrospective comparative
Risk of bias: Critical
Amiodarone versus metoprolol  < 100 bpm within 24 h from initiation of treatment:
p = 1.00
Amiodarone: 85.2% Metoprolol: 87.5%
p = 0.013
Amiodarone: 21.3%
Metoprolol: 37.5%
Not assessed
Jaffer et al. (2016) (conference abstract) n = 65
Setting: USA ICU
Septic shock Retrospective comparative
Risk of bias: Critical
Amiodarone versus beta blockers (drug not specified) Not assessed Not assessed NS
McKenzie Brown et al. (2018) n = 33e
n = 6 (amiodarone)
n = 22 (beta blockers)
Setting: USA
surgical ICU
Noncardiac surgical population Retrospective comparative
Risk of bias: critical
Amiodarone versus beta blockers (drug not specified) p = 0.001
Amiodarone: 83%
Beta blockers: 27%f
p = 0.001
Amiodarone: 83%
Beta blockers: 27%f
Not compared between treatment groups
  1. aIncludes calcium channel blockers and digoxin groups
  2. bRelative risk
  3. cStatistically not significant
  4. dIncludes propafenone group
  5. eIncludes calcium channel blockers and no treatment groups